United Therapeutics (UTHR) EBIT (2009 - 2026)

United Therapeutics has disclosed EBIT across 18 years of filings, most recently posting $330.8 million for Q2 2026.

• In Q2 2026, EBIT fell 9.25% year-over-year to $330.8 million; the TTM figure through Jun 2026 stood at $1.4 billion (down 3.2% YoY), while the FY2025 annual figure was $1.5 billion, up 8.39% from the prior year.
• EBIT came in at $330.8 million for Q2 2026 at United Therapeutics, up from $325.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $388.5 million in Q3 2025 to a low of $175.6 million in Q4 2022.
• Average EBIT over 5 years is $316.2 million, with a median of $326.4 million recorded in 2023.
• Year-over-year, EBIT surged 544.44% in 2022 and dropped 14.89% in 2026.
• Over 5 years, EBIT stood at $175.6 million in 2022, then soared by 48.12% to $260.1 million in 2023, then jumped by 37.52% to $357.7 million in 2024, then slipped by 0.28% to $356.7 million in 2025, then slipped by 7.26% to $330.8 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $330.8 million in Q2 2026, $325.8 million in Q1 2026, and $356.7 million in Q4 2025.